Jan 23, 2026
Newsroom
The U.S. NCCN Guidelines Included Ropeginterferon alfa-2b-njft (P1101) as a Recommended Treatment Option for Patients with Essential Thrombocythemia (ET)
Learn MoreJan 13, 2026
Newsroom
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
Learn MoreJan 12, 2026
Newsroom
PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
Learn MoreDec 24, 2025
Newsroom
PharmaEssentia USA Announces Appointment of Jeffrey Williams as Independent Director
Learn MoreNov 25, 2025
Newsroom
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
Learn MoreNov 11, 2025
Newsroom
PharmaEssentia USA Announces Appointment of Dr. Barry Flannelly as Independent Director
Learn MoreOct 6, 2025
Newsroom
Material Information - Hong Kong Department of Health has Approved the New Drug Registration of BESREMi (Ropeginterferon alfa-2b) for PV
Learn MoreSep 22, 2025
Newsroom
Material Information - Announcement of the U.S. FDA’s Positive Preliminary Comments on the Filing for Expansion of Indication of BESREMi for Essential Thrombocythemia (ET)
Learn MoreSep 18, 2025
Newsroom
Material Information - Announcement on Behalf of PharmaEssentia Japan KK: Filing for an Additional Indication of BESREMi (Ropeginterferon alfa-2b) for ET in Japan
Learn MoreSep 11, 2025
Newsroom
Material Information - The Health Canada has Accepted the New Drug Submission of Ropeginterferon alfa-2b for PV
Learn MoreSep 5, 2025
Newsroom
Material Information - PharmaEssentia Files for an Additional Indication of Besremi (Ropeginterferon alfa-2b) for the Treatment of Essential Thrombocythemia (ET) with TFDA
Learn More